The material on this site is for financial institutions, professional investors and their professional advisers. It is for information only. Please read our Terms & Conditions, Privacy Policy and Cookies before using this site. Please see our Subscription Terms and Conditions.


All material subject to strictly enforced copyright laws. © 2021 Euromoney, a part of the Euromoney Institutional Investor PLC.
Opinion

Merger meddling may leave French companies exposed

Have French efforts to create a national champion in the pharmaceuticals industry left its companies more vulnerable to hostile takeovers?

One of Europe's most contentious takeover battles in years was finally brought to a close last month when a beleaguered Aventis, under intense pressure from the French government, accepted a sweetened $63 billion takeover bid from rival French pharmaceutical company Sanofi-Synthélabo.

The combined company, to be called Sanofi-Aventis, will be the third-largest pharmaceutical company in the world behind US company Pfizer and GlaxoSmithKline of the UK.

The deal will create a single French powerhouse with dominant market shares in cancer, allergy and anti-stroke drugs.

But according to French lawyers, the government?s heavy-handed tactics in pushing the merger through could have a decidedly unhealthy effect on the French mergers and acquisitions market, potentially chilling foreign investment into the region while at the same time leaving French companies more vulnerable to raiders.

Specifically, French companies may find that their defences are sharply limited in trying to fend off hostile takeover attempts, after stock market regulator Authorité des Marchés Financiers (AMF) rejected Aventis?s poison pill plan to issue warrants tied to the patent protection of one of Sanofi's best-selling drugs.

?The AMF ruling could be a big step backwards for the French market,? says Eric Cafritz, a partner at the Paris office of law firm Fried Frank Harris Shriver & Jacobson.

You have reached premium content. Please log in to continue reading.

Read beyond the headlines with Euromoney

For over 50 years, our readers have looked to Euromoney to stay informed about the issues that matter in the international banking and financial markets. Find out more about our different levels of access below.

SUBSCRIBE ONLINE TODAY

Unlimited access to Euromoney.com and Asiamoney.com

Expert comment, long reads and in-depth analysis interviews with senior finance professionals

Access the results of our market-leading annual surveys across core financial services

Access the results of our annual awards, including the world-renowned Awards for Excellence

Your print copy of Euromoney magazine delivered monthly

£73.75 per month

Billed Annually

FREE 7 DAY TRIAL

Unlimited access to Euromoney.com and Asiamoney.com, including our top stories, long reads, expert analysis, and the results of our annual surveys and awards

Sign up to any of our newsletters, curated by our editors

LOGIN NOW

Already a user?

We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree